康艾注射液联合美罗华治疗恶性淋巴瘤的临床疗效及安全性研究  

Clinical efficacy and safety of Kang＇ai injection combined with rituximab in the treatment of malignant lymphoma

作　　者：潘清文[1] 陈哲[1] 罗俭权 陈达勇[1] 

机构地区：[1]四会市人民医院普外科,526200

出　　处：《国际医药卫生导报》2016年第21期3245-3247,共3页International Medicine and Health Guidance News

摘　　要：目的探讨康艾注射液联合美罗华治疗恶性淋巴瘤的临床疗效，并对其安全性进行评价。方法选择2014年6月至2015年6月于本院就诊的82例恶性淋巴瘤患者作为研究对象。对照组仅给予美罗华治疗，观察组在对照组的治疗基础上另给予康艾注射液。比较两组患者治疗效果，观察两组患者不良反应发生情况，治疗前后分别检测两组患者神经元特异性烯醇化酶（NSE）、细胞角蛋白19片段（CYFRA21—1）及恶性肿瘤特异生长因子（TSGF）含量。结果治疗后，观察组CR率、PR率及总有效率分别为51．2％、36．6％及87．8％，均明显高于对照组，PD率则为0．0％，明显低于对照组；所有患者治疗期间均未出现严重不良反应；观察组患者治疗后NSE、CYFRA21—1及TSGF均得到明显改善。结论康艾注射液联合美罗华治疗恶性淋巴瘤可有效提高治疗效果且安全性较好，值得进行进一步研究。Objective To investigate the clinical efficacy and safety of Kang＇ai injection combined with rituximab in the treatment of malignant lymphoma. Methods 82 patients with malignant lymphoma in our hospital from June 2014 to June 2015 were selected as study subjects. Control group only received rituximab treatment, observation group was given Kang＇ai injection on the basis of control group. Compared the treatment effect, observed the incidence of adverse reactions, detected the levels of neuron specific enolase （NSE）, cytokeratin 19 fragment （CYFRA21-1）, and malignant tumor specific growth factor （TSGF） before and after treatment. Results After treatment, CR rate, PR rate and the total effective rate of observation group were 51.2%, 36.6%, and 87.8% respectively, significantly higher than those of control group, PD rate was 0%, significantly lower than that of control group. There were no serious adverse reactions in all patients during treatment. NSE, CYFRA21-1, and TSGF significantly improved after treatment in observation group. Conclusion Kang＇ai injection combined with rituximab in the treatment of malignant lymphoma can effectively improve the therapeutic effect, with good security, worthy of further study.

关 键 词：康艾注射液 美罗华 恶性淋巴瘤 

分 类 号：R733.4[医药卫生—肿瘤]